DK1124804T3 - Inhibitorer for biosyntesen af prostaglandin-endoperoxid-H-syntase - Google Patents

Inhibitorer for biosyntesen af prostaglandin-endoperoxid-H-syntase

Info

Publication number
DK1124804T3
DK1124804T3 DK99953259T DK99953259T DK1124804T3 DK 1124804 T3 DK1124804 T3 DK 1124804T3 DK 99953259 T DK99953259 T DK 99953259T DK 99953259 T DK99953259 T DK 99953259T DK 1124804 T3 DK1124804 T3 DK 1124804T3
Authority
DK
Denmark
Prior art keywords
cox
inhibitors
cyclooxygenase
biosynthesis
synthase
Prior art date
Application number
DK99953259T
Other languages
Danish (da)
English (en)
Inventor
Lawrence A Black
Anwer Basha
Teodozyj Kolasa
Michael E Kort
Meena V Patel
Jeffrey J Rohde
Michael J Coghlan
Andrew O Stewart
Huaqing Liu
Catherine M Mccarty
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Priority claimed from US09/427,768 external-priority patent/US6307047B1/en
Application granted granted Critical
Publication of DK1124804T3 publication Critical patent/DK1124804T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK99953259T 1998-10-27 1999-10-27 Inhibitorer for biosyntesen af prostaglandin-endoperoxid-H-syntase DK1124804T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17960598A 1998-10-27 1998-10-27
US26187299A 1999-03-03 1999-03-03
US29849099A 1999-04-23 1999-04-23
US09/427,768 US6307047B1 (en) 1997-08-22 1999-10-27 Prostaglandin endoperoxide H synthase biosynthesis inhibitors

Publications (1)

Publication Number Publication Date
DK1124804T3 true DK1124804T3 (da) 2005-12-12

Family

ID=27497355

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99953259T DK1124804T3 (da) 1998-10-27 1999-10-27 Inhibitorer for biosyntesen af prostaglandin-endoperoxid-H-syntase

Country Status (19)

Country Link
EP (1) EP1124804B1 (de)
JP (1) JP2003512292A (de)
KR (1) KR100666838B1 (de)
CN (1) CN1279026C (de)
AT (1) ATE302759T1 (de)
BG (1) BG65261B1 (de)
BR (1) BR9914858A (de)
CA (1) CA2347982A1 (de)
CZ (1) CZ300570B6 (de)
DE (1) DE69926903T2 (de)
DK (1) DK1124804T3 (de)
ES (1) ES2249919T3 (de)
HK (1) HK1041876B (de)
HU (1) HUP0105248A3 (de)
NO (1) NO318623B1 (de)
PL (1) PL198503B1 (de)
SK (1) SK286806B6 (de)
TR (1) TR200101765T2 (de)
WO (1) WO2000024719A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1142148C (zh) 1997-11-19 2004-03-17 兴和株式会社 新颖的哒嗪衍生物和含有其作为有效成分的药物
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
JP2000247959A (ja) 1999-02-26 2000-09-12 Kowa Co ピリダジン−３−オン誘導体及びこれを含有する医薬
US6664256B1 (en) 2000-07-10 2003-12-16 Kowa Co., Ltd. Phenylpyridazine compounds and medicines containing the same
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
AR031129A1 (es) 2000-09-15 2003-09-10 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
MY131964A (en) 2000-09-15 2007-09-28 Pharmacia Corp 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
US7012098B2 (en) 2001-03-23 2006-03-14 Pharmacia Corporation Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
DE10129320A1 (de) 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
ES2334990T3 (es) 2002-02-14 2010-03-18 Pharmacia Corporation Piridinonas sustituidas como moduladores de p38 map quinasa.
RU2331438C2 (ru) 2002-12-13 2008-08-20 Уорнер-Ламберт Компани Ллс Альфа-2-дельта лиганд для лечения симптомов нижних мочевыводящих путей
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
ES2211344B1 (es) * 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
MXPA05009972A (es) 2003-03-18 2005-11-04 Kowa Co Derivado de fenilpiridazina soluble en agua y medicina que contiene el mismo.
PL1534305T3 (pl) 2003-05-07 2007-03-30 Osteologix As Leczenie zaburzeń chrząstek i kości solami strontu rozpuszczalnymi w wodzie
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
US7728031B2 (en) 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
EP1916240A1 (de) * 2006-10-25 2008-04-30 Syngeta Participations AG Neue Pyridazin-Derivate
WO2008077599A1 (en) 2006-12-22 2008-07-03 Recordati Ireland Limited COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH α2δ LIGANDS AND NSAIDS
DE102007008843A1 (de) 2007-02-23 2008-08-28 Bayer Healthcare Ag Verfahren zur Herstellung von 4,5-Dihalogen-2-aryl-2H-pyridazin-3-onen
DE102007008840A1 (de) 2007-02-23 2008-08-28 Bayer Healthcare Ag Neue polymorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-methyl-1-butoxy)-5-[4-methylsulfonyl)phenyl]-3(2H)-pyridazinon (FHMP)
DE102007008839A1 (de) * 2007-02-23 2008-08-28 Bayer Healthcare Ag Verfahren zur Herstellung von 4-(3-Hydroxy-3-methyl-butoxy)-5-[4-(methylsulfonyl)phenyl]-2-arylpyridazin-3(2H)-onen
DE102007020689A1 (de) * 2007-05-03 2008-11-06 Bayer Healthcare Ag Neue polymorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-methyl-1-butoxy-5-[4-methylsulfonyl)phenyl]3/2H)-pyridazinon (FHMP)
DE102007020690A1 (de) * 2007-05-03 2008-11-06 Bayer Healthcare Ag Neue amorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-mehtyl-1-butoxy)-6[4-methylsulfonyl)phenyl]-3(2H)-pyridazinon (FHMP)
DE102007025717A1 (de) * 2007-06-01 2008-12-11 Merck Patent Gmbh Arylether-pyridazinonderivate
GB0716414D0 (en) * 2007-08-22 2007-10-03 Syngenta Participations Ag Novel insecticides
EP2188288A1 (de) 2007-09-11 2010-05-26 Abbott Laboratories Octahydropyrrolo[3,4-b]pyrrol-n-oxide
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
JP2012131708A (ja) * 2009-04-28 2012-07-12 Nissan Chem Ind Ltd ４位置換ピリダジノン化合物及びｐ２ｘ７受容体阻害剤
FR2969606B1 (fr) * 2010-12-22 2013-01-11 Pf Medicament Derives de diarylpyridazinones, leur preparation et leur application en therapeutique humaine
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
CN107334767B (zh) * 2017-06-08 2019-03-05 中国医学科学院医药生物技术研究所 一种哒嗪酮类化合物在肿瘤治疗中的应用
WO2021124344A1 (en) * 2019-12-18 2021-06-24 Abida Pyridazine derivatives and their use as cyclooxygenase-2 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4238490A (en) * 1979-02-12 1980-12-09 Diamond Shamrock Corporation Antihypertensive pyridazin(2H)-3-ones
WO1982000402A1 (en) * 1980-08-07 1982-02-18 Shamrock Corp Diamond Herbicidal and plant growth regulant diphenylpyridazinones
US5622948A (en) * 1994-12-01 1997-04-22 Syntex (U.S.A.) Inc. Pyrrole pyridazine and pyridazinone anti-inflammatory agents
EP0833664A1 (de) * 1995-06-12 1998-04-08 G.D. SEARLE & CO. Kombination aus einem cyclooxygenase-2 inhibitor und einem leukotrien b4 rezeptorantagonisten zur behandlung von entzündungen
ATE271547T1 (de) * 1997-03-14 2004-08-15 Merck Frosst Canada Inc Pyridazinone als inhibitoren von cyclooxygenase-2
EP1007515A1 (de) * 1997-08-22 2000-06-14 Abbott Laboratories Arylpyridazinone als hemmer der biosynthese der prostaglandin-endoperoxid-h-synthase
ATE319691T1 (de) * 1997-08-22 2006-03-15 Abbott Lab Prostaglandin endoperoxyde h synthase biosynthese inhibitoren
NZ501808A (en) * 1997-08-22 2002-12-20 Abbott Lab Arylpyridazinones and their use as prostaglandin endoperoxide H synthase biosynthesis inhibitors

Also Published As

Publication number Publication date
BR9914858A (pt) 2002-02-05
PL198503B1 (pl) 2008-06-30
HK1041876B (zh) 2006-06-23
TR200101765T2 (tr) 2002-02-21
NO20012061L (no) 2001-06-27
CN1342149A (zh) 2002-03-27
NO318623B1 (no) 2005-04-18
CA2347982A1 (en) 2000-05-04
HUP0105248A2 (hu) 2002-07-29
PL349256A1 (en) 2002-07-01
SK286806B6 (sk) 2009-05-07
EP1124804B1 (de) 2005-08-24
CZ20011481A3 (cs) 2001-09-12
ES2249919T3 (es) 2006-04-01
SK5542001A3 (en) 2001-12-03
BG65261B1 (bg) 2007-10-31
KR100666838B1 (ko) 2007-01-11
JP2003512292A (ja) 2003-04-02
ATE302759T1 (de) 2005-09-15
CN1279026C (zh) 2006-10-11
EP1124804A1 (de) 2001-08-22
HUP0105248A3 (en) 2002-09-30
NO20012061D0 (no) 2001-04-26
DE69926903D1 (en) 2005-09-29
HK1041876A1 (en) 2002-07-26
CZ300570B6 (cs) 2009-06-17
WO2000024719A1 (en) 2000-05-04
KR20010081101A (ko) 2001-08-27
BG105523A (en) 2001-12-29
DE69926903T2 (de) 2006-07-13

Similar Documents

Publication Publication Date Title
DK1124804T3 (da) Inhibitorer for biosyntesen af prostaglandin-endoperoxid-H-syntase
CA2299300A1 (en) Arylpyridazinones as prostaglandin endoperoxide h synthase bisoynthesis inhibitors
DK1005460T3 (da) Inhibitorer af biosyntesen af prostaglandin-endoperoxid H-synthase
Carabaza et al. Stereoselective inhibition of inducible cyclooxygenase by chiral nonsteroidal antiinflammatory drugs
Frölich A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes
Zarghi et al. Synthesis and biological evaluation of 1, 3-diphenylprop-2-en-1-ones possessing a methanesulfonamido or an azido pharmacophore as cyclooxygenase-1/-2 inhibitors
Sies et al. Functions of glutathione in liver and kidney
Denkert et al. Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference
BRPI0011172B8 (pt) derivados do 4,5-diaril-3(2h)-furanona como inibidores de ciclooxigenase-2
Thérien et al. Synthesis and biological evaluation of 5, 6-diarylimidazo [2.1-b] thiazole as selective COX-2 inhibitors
Chen et al. Syntheses and biological activities of sulfoximine-based acyclic triaryl olefins
Brunell et al. Studies on the metabolism and biological activity of the epimers of sulindac
TR200000447T2 (tr) 5-Alkil-2-arilaminofenilasetik asitler ve türevleri.
Petrovic et al. Using N, N, N’, N’-tetramethyl-p-phenylenediamine (TMPD) to assay cyclooxygenase activity in vitro
Aprioku et al. Renal effects of non-steroidal anti inflammatory drugs in albino rats
FR2897864B1 (fr) Composition d'amorcage et applications
TR200000478T2 (tr) Prostaglandin endoperoksit H sentaz biyosentezi inhibitörleri olarak arilpiridazinonlar.
McCulloch et al. Fluorescent Mechanism‐Based Probe for Aerobic Flavin‐Dependent Enzyme Activity
Tavares The effects of meloxicam, indomethacin or NS‐398 on eicosanoid synthesis by fresh human gastric mucosa
Liang et al. 20‐Hydroxyeicosatetraenoic acid inhibits ATP‐induced COX‐2 expression via peroxisome proliferator activator receptor‐α in vascular smooth muscle cells
Lau et al. From indomethacin to a selective COX-2 inhibitor: development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors
Rai et al. Synthesis of Some Novel 2‐[2‐(aroyl‐aroxy)‐methyl]‐4‐phenyl‐1, 3‐thiazoles as Potent Anti‐Inflammatory Agents
Izzo et al. Cyclooxygenase in GtoPdb v. 2023.1
Khanapure et al. 3-[4-(Methylsulfonyl) phenyl]-5-(trifluoromethyl)(2-pyridyl) phenyl ketone as a potent and orally active cyclooxygenase-2 selective inhibitor: Synthesis and biological evaluation
Panico et al. “In vitro” differences among (R) and (S) enantiomers of profens in their activities related to articular pathophysiology